CONOPHYLLINE
| 中文名稱 | CONOPHYLLINE |
|---|---|
| 中文同義詞 | 長(zhǎng)春花堿 III-121C;長(zhǎng)春堿衍生物;長(zhǎng)春花生物堿III-121C;化合物 T13624;硫酸長(zhǎng)春新堿雜質(zhì)10 |
| 英文名稱 | Cophylline |
| 英文同義詞 | Cophylline;Vinca alkaloid III-121C;[8,15'-Biaspidospermidine]-3,3'-dicarboxylic acid, 2,2',3,3'-tetradehydro-6',7':7,16'-diepoxy-6,15-dihydroxy-16,17-dimethoxy-, dimethyl ester, (5α,6β,7α,8α,12R,19α)-(5'α,6'β,7'β,12'R,19'α)-;[8,15'-Biaspidospermidine]-3,3'-dicarboxylicacid,2,2',3,3'-tetradehydro-6',7':7,16'-diepoxy-6,15-dihydroxy-16,17-dimethoxy-,dimethyl ester, (5a,6b,7a,8a,12R,19a)-(5'a,6'b,7'b,12'R,19'a)-;Vincristine Impurity 10 |
| CAS號(hào) | 142741-24-0 |
| 分子式 | C44H50N4O10 |
| 分子量 | 794.9 |
| EINECS號(hào) | |
| 相關(guān)類別 | 標(biāo)準(zhǔn)品;植物提取物;標(biāo)準(zhǔn)品 -對(duì)照藥材;生物堿 |
| Mol文件 | 142741-24-0.mol |
| 結(jié)構(gòu)式 |  |
CONOPHYLLINE 性質(zhì)
| 密度 | 1.53±0.1 g/cm3(Predicted) |
|---|---|
| 儲(chǔ)存條件 | Store at -20°C |
| 酸度系數(shù)(pKa) | 10.73±0.70(Predicted) |
Conophylline (100 ng/ml; 48 hours) reproduces differentiationinducing activity but not apoptosis-inducing activity of activin.
Conophylline (100 ng/ml; 72 hours) exhibits the differentiation-inducing activity in AR42J cells and converts these cells to endocrine cells.
Conophylline increases the expression of neurogenin-3 by activating p38 mitogen-activated protein kinase to induce differentiation of AR42J cells.
Conophylline reduces the expression of α-SMA and collagen-1 in rat HSC and Lx-2 cells.
Conophylline inhibits DNA synthesis induced by serum.
Conophylline also promots activation of caspase-3 and induces apoptosis in Lx-2 Cells.
Apoptosis Analysis
| Cell Line: | Lx-2 Cells |
| Concentration: | 12 hours |
| Incubation Time: | 0.1 μg/ml |
| Result: | Induced apoptosis |
Western Blot Analysis
| Cell Line: | Lx-2 cells |
| Concentration: | 0.1 μg/ml |
| Incubation Time: | 15 minutes, 30 minutes, 60 minutes, 120 minutes |
| Result: | Increased phospho-JNK. |
Conophylline (0.9 mg/kg; p.o.; daily; for 12 weeks) attenuates formation of the liver fibrosis induced by TAA in vivo.
| Animal Model: | Sprague-Dawley rats (70-80 g) |
| Dosage: | 0.9 mg/kg |
| Administration: | Oral administration; daily; for 12 weeks |
| Result: | Attenuated formation of the liver fibrosis induced by TAA. |